Data

The use of the cost minimisation approach in Health Technology Assessment submissions to the Australian Pharmaceutical Benefits Advisory Committee

Macquarie University
Alicia Norman (Aggregated by) Bonny Parkinson (Aggregated by) Martin Hoyle (Aggregated by) Sean Lybrand (Aggregated by) Zachary Tirrell (Aggregated by)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.25949/26308576.v1&rft.title=The use of the cost minimisation approach in Health Technology Assessment submissions to the Australian Pharmaceutical Benefits Advisory Committee&rft.identifier=https://doi.org/10.25949/26308576.v1&rft.publisher=Macquarie University&rft.description=Data collected to support analysis of the use of the cost minimisation approach (CMA) in Health Technology Assessment submissions to the Australian Pharmaceutical Benefits Advisory Committee. All public summary documents (PSD) available online from meetings between July 2005 and December 2022 (inclusive) were downloaded [1] and matched to the PBAC outcomes [2]. PSDs were searched for terminology related to cost minimisation (cost-minimisation, cost minimisation, and CMA) for relevance to the research. Relevant PSDs were manually reviewed for inclusion criteria, including being a major submission (or category 1 and 2 between 2021 and 2022) using CMA for an eligible product type. For eligible submissions, data was collected by a single reviewer through a holistic review of PSDs and subsequently supplemented by targeted keyword searches for validation. A second reviewer assessed accuracy for a 5% sample, which had 90% initial concordance. Differences were deliberated and resolved through consensus, resulting in the retention of 97% of the initially coded data. Copyright Notice: The Department of Health and Aged Care owns the copyright in the Pharmaceutical Benefits Advisory Committee Public Summary Documents and Outcomes. These materials are © Commonwealth of Australia, used under license. Permitted use of this data requires the inclusion of a copyright notice as follows: '© Commonwealth of Australia'. Licence Exclusion: The data comprised in the following columns are reproduced from material which is © Commonwealth of Australia and are excluded from the CC BY-NC-SA licence: - Matched Web Outcomes Text - PBAC Outcomes column 1 - PBAC Outcomes column 2 - PBAC Outcomes column 3 - PBAC Outcomes column 4 - PBAC Outcomes column 5 - Reasons for rejection This content has been reproduced for inclusion within this dataset with the express permission of the Australian Department of Health and Aged Care. The content cannot be further reproduced without the permission of the Australian Department of Health and Aged Care.  &rft.creator=Alicia Norman&rft.creator=Bonny Parkinson&rft.creator=Martin Hoyle&rft.creator=Sean Lybrand&rft.creator=Zachary Tirrell&rft.date=2024&rft_rights=CC-BY-NC-SA-4.0&rft_subject=Pharmacoeconomics&rft_subject=health technology assessment (HTA)&rft_subject=Pharmaceutical Benefits Advisory Committee (PBAC)&rft_subject=Pharmacoeconomics and health outcomes&rft_subject=drug coverage&rft_subject=Health economics&rft.type=dataset&rft.language=English Access the data

Licence & Rights:

Non-Commercial Licence view details
CC-BY-NC-SA

CC-BY-NC-SA-4.0

Full description

Data collected to support analysis of the use of the cost minimisation approach (CMA) in Health Technology Assessment submissions to the Australian Pharmaceutical Benefits Advisory Committee.

All public summary documents (PSD) available online from meetings between July 2005 and December 2022 (inclusive) were downloaded [1] and matched to the PBAC outcomes [2]. PSDs were searched for terminology related to cost minimisation ("cost-minimisation", "cost minimisation", and "CMA") for relevance to the research. Relevant PSDs were manually reviewed for inclusion criteria, including being a major submission (or category 1 and 2 between 2021 and 2022) using CMA for an eligible product type.

For eligible submissions, data was collected by a single reviewer through a holistic review of PSDs and subsequently supplemented by targeted keyword searches for validation. A second reviewer assessed accuracy for a 5% sample, which had 90% initial concordance. Differences were deliberated and resolved through consensus, resulting in the retention of 97% of the initially coded data.


Copyright Notice:

The Department of Health and Aged Care owns the copyright in the Pharmaceutical Benefits Advisory Committee Public Summary Documents and Outcomes. These materials are © Commonwealth of Australia, used under license. Permitted use of this data requires the inclusion of a copyright notice as follows: '© Commonwealth of Australia'.


Licence Exclusion:

The data comprised in the following columns are reproduced from material which is

© Commonwealth of Australia and are excluded from the CC BY-NC-SA licence:

- Matched Web Outcomes Text

- PBAC Outcomes column 1

- PBAC Outcomes column 2

- PBAC Outcomes column 3

- PBAC Outcomes column 4

- PBAC Outcomes column 5

- Reasons for rejection

This content has been reproduced for inclusion within this dataset with the express permission of the Australian Department of Health and Aged Care. The content cannot be further reproduced without the permission of the Australian Department of Health and Aged Care.
 

Issued: 2024-08-01

Created: 2024-08-01

This dataset is part of a larger collection

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers